First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
Adynovate in combination with Mypkfit offers personalized treatment and enables HCPs and patients to monitor factor levels from home and help achieve optimum QOL outcomes
The licences will allow manufacturers from around the world to work with MPP and C-TAP to make these technologies accessible to people living in low- and middle-income countries
The new framework collaboration will support due diligence into ALSA’s potential investments, which will assist with their investment de-risking
Ahead of International Thalassemia Day on 8th May, medical professionals and representatives of patient bodies participated in a virtual discussion on the current situation of Thalassemia management in India
There is a need for the Ministry of Health to put it on the priority list and address the issues, which are numerous
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
It is the first hospital in the country to achieve the significant milestone of completing over 2600 robotic surgeries for treating patients with prostate, kidney and urinary bladder cancer
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
Subscribe To Our Newsletter & Stay Updated
